Clinical Scorecard: The Role of Fibroblast Growth Factor 23 in Atrial Fibrillation Outcomes: Clinical Associations and Genetic Insights
At a Glance
Category
Detail
Condition
Atrial fibrillation (AF)
Key Mechanisms
Fibroblast growth factor 23 (FGF23) influences mineral homeostasis and bone health; elevated FGF23 levels are associated with increased arrhythmogenesis and cardiovascular outcomes in AF patients.
Target Population
Patients diagnosed with atrial fibrillation
Care Setting
Clinical and genetic research settings with potential application in cardiovascular disease management
Key Highlights
Elevated serum FGF23 levels in AF patients are significantly associated with increased risks of all-cause mortality, cardiovascular mortality, and heart failure.
A polygenic score for FGF23 (PGSFGF23) shows paradoxical associations: genetically increased FGF23 is linked to reduced heart failure risk but increased all-cause mortality and ischemic stroke risk.
FGF23 is a potential biomarker for prognostic assessment in AF, but further studies are needed to clarify underlying mechanisms due to conflicting genetic and serum level associations.
Guideline-Based Recommendations
Diagnosis
Consider measuring serum FGF23 levels in AF patients to assess risk stratification for mortality and heart failure.
Utilize polygenic scoring cautiously as genetic associations with outcomes are complex and require further validation.
Management
Integrate FGF23 level assessment into comprehensive AF management to potentially identify high-risk patients.
Further research is needed before FGF23-targeted therapies can be recommended.
Monitoring & Follow-up
Monitor serum FGF23 levels longitudinally in AF patients to evaluate progression risk of heart failure and mortality.
Genetic monitoring via polygenic scores may inform risk but is not yet standard clinical practice.
Risks
Elevated serum FGF23 is associated with increased risk of mortality and heart failure in AF patients.
Genetically elevated FGF23 may increase risk of ischemic stroke and mortality despite reduced heart failure risk, indicating complex risk profiles.
Patient & Prescribing Data
Atrial fibrillation patients with available serum FGF23 measurements and genetic data
Current evidence supports the prognostic value of serum FGF23 but does not yet inform specific therapeutic interventions; genetic data highlight the need for personalized risk assessment.
Clinical Best Practices
Incorporate serum FGF23 measurement in AF patient evaluations to improve prognostic accuracy for mortality and heart failure.
Use polygenic risk scores for FGF23 cautiously, acknowledging the paradoxical genetic associations and the need for further research.
Maintain comprehensive cardiovascular risk management in AF patients alongside emerging biomarker assessments.
Encourage further studies to elucidate mechanisms linking FGF23 levels and genetic variants with AF outcomes.
